title: Erythema migrans in the immunocompromised host.
abstract: From 1990 to 1996 a total of 67 adult patients with typical erythema migrans (EM) and a previously identified immunocompromised condition were investigated at the University Medical Centre, Department of Infectious Diseases, Ljubljana, Slovenia. The course and outcome of borrelial infection were compared with 67 previously healthy age and sex-matched individuals with EM who were examined at our institution in the same year. Clinical characteristics of Lyme borreliosis before treatment and the duration of EM after the institution of therapy with antibiotics including amoxicillin, azithromycin, cefuroxime-axetil, doxycycline, and ceftriaxone were comparable in both groups. The occurrence of early disseminated borrelial infection before treatment and the frequency of treatment failure (defined as the onset of severe minor or major manifestations of Lyme borreliosis, persistence of B. burgdorferi sensu lato in the skin and/or persistence of EM after treatment) were found significantly more often in immunocompromised patients than in the control group (16/67 versus 6/67, respectively; p = 0.0358). Re-treatment was required in 13 (19.4%) patients of the immunocompromised group and only in five (7.5%) patients of the control group (p = 0.0762). However, in spite of the more severe course and the more frequent need for re-treatment among patients whose immune system was impaired, the outcome of borrelial infection after one year was favourable in both groups.
authors.affiliation: Department of Infectious Diseases, University Medical Centre, Ljubljana, Slovenia.
authors.forename: V
authors.initials: V
authors.lastname: Maraspin
authors.forename: S
authors.initials: S
authors.lastname: Lotric-Furlan
authors.forename: J
authors.initials: J
authors.lastname: Cimperman
authors.forename: E
authors.initials: E
authors.lastname: Ruzić-Sabljić
authors.forename: F
authors.initials: F
authors.lastname: Strle
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015787:Erythema Chronicum Migrans / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008193:Lyme Disease / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy*; D011446:Prospective Studies; D019233:Retreatment; D017524:Slovenia; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents